

**SEQ ID NO:3 aligned with Biogen's SEQ ID NO:3**

<!--StartFragment-->RESULT 1  
AAB60699  
ID AAB60699 standard; protein; 302 AA.  
XX  
AC AAB60699;  
XX  
DT 11-SEP-2003 (revised)  
DT 22-MAY-2001 (first entry)  
XX  
DE Mouse IgG signal/human BAFF-R/human IgG Fc fusion protein, BAFF-R-Fc.  
XX  
KW Human BAFF-R; BAFF receptor; TNF family; immunoregulatory agent;  
KW immune-related disorder; B-cell growth inhibitor;  
KW B-cell maturation inhibitor; immunoglobulin production inhibitor;  
KW autoimmune disorder; B-cell lymphoproliferative disorder; hypertension;  
KW renal disorder; immunosuppressive disorder; HIV infection;  
KW organ transplantation; antiinflammatory; systemic lupus erythematosus;  
KW autoimmune haemolytic anaemia; Grave's disease; multiple myeloma;  
KW B-cell carcinoma; leukaemia; rapidly progressive glomerulonephritis;  
KW lymphoma; gene therapy; cancer; tumour; IgG Fc; fusion construct.  
XX  
OS Homo sapiens.  
OS Mus sp.  
OS Chimeric.  
XX  
PN WO200112812-A2.  
XX  
PD 22-FEB-2001.  
XX  
PF 16-AUG-2000; 2000WO-US022507.  
XX  
PR 17-AUG-1999; 99US-0149378P.  
PR 11-FEB-2000; 2000US-0181684P.  
PR 18-FEB-2000; 2000US-0183536P.  
XX  
PA (BIOJ ) BIOGEN INC.  
PA (APOT-) APOTECH R & D SA.  
XX  
PI Mackay F, Browning J, Ambrose C, Tschopp J, Schneider P;  
PI Thompson J;  
XX  
DR WPI; 2001-202866/20.  
DR N-PSDB; AAF59999.  
XX  
PT Inhibiting dendritic cell-induced B-cell growth, maturation and B-cell  
PT lympho-proliferative disorder by administering BAFF-receptor polypeptide,  
PT chimeric molecule comprising receptor or anti-BAFF-R antibody homolog.  
XX  
PS Example 4; Fig 2; 59pp; English.  
XX  
CC The invention relates to the use of a BAFF receptor (BAFF-R, also known  
CC as BCMA) protein, or a BAFF-R fusion protein as an agent for the  
CC treatment of a variety of immune-related disorders. BAFF-R is a member of  
CC the TNF (tumour necrosis factor) family, acting as an immunoregulatory  
CC agent, and also plays a role in the development of hypertension and  
CC related disorders. BAFF-R, fusion proteins containing it, and BAFF-R-  
CC specific antibodies can be used for inhibiting B-cell growth, dendritic  
CC cell-induced B-cell growth and maturation, and immunoglobulin production,  
CC and in the treatment of autoimmune disorders, B-cell lymphoproliferative  
CC disorders, hypertension and renal disorders. The BAFF-R proteins may also  
CC be used in the treatment of immunosuppressive disorders and HIV

CC infection, and in patients undergoing organ transplantation. The BAFF-R  
 CC proteins or BAFF-R specific antibodies may be used for treating,  
 CC suppressing or altering an immune response involving a signalling pathway  
 CC between BAFF-R and BAFF, thereby inhibiting inflammation. Since BAFF-R  
 CC inhibits B-cell growth and maturation it is useful for treating diseases  
 CC such as systemic lupus erythematosus, autoimmune haemolytic anaemia,  
 CC Grave's disease, multiple myeloma, B-cell carcinomas, leukaemia, rapidly  
 CC progressive glomerulonephritis, and lymphomas. Nucleic acids encoding  
 CC human BAFF-R may be used in gene therapy to treat tumours, lymphomas,  
 CC autoimmune disorders and inherited B-cell-associated disorders. The  
 CC present sequence represents the BAFF-R fusion protein BAFF-R-Fc,  
 CC comprising a mouse IgG-kappa signal sequence, residues 1-153 of human  
 CC BAFF-R and a human IgG Fc sequence. (Updated on 11-SEP-2003 to  
 CC standardise OS field)

XX

SQ Sequence 302 AA;

Query Match 100.0%; Score 1643; DB 4; Length 302;  
 Best Local Similarity 100.0%; Pred. No. 6.4e-112;  
 Matches 302; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 METDTLLLWVLLWVPGSTGDVTMLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTC 60  
 |||||||

Db 1 METDTLLLWVLLWVPGSTGDVTMLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTC 60

Qy 61 QRYCNASVTNSVKGVDKTHCPPCPAPELLGGPSVLFPPKPKDTLMISRTPETCVVVD 120  
 |||||||

Db 61 QRYCNASVTNSVKGVDKTHCPPCPAPELLGGPSVLFPPKPKDTLMISRTPETCVVVD 120

Qy 121 VSHEDEPVKFNWWYVDGVEVHNAAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN 180  
 |||||||

Db 121 VSHEDEPVKFNWWYVDGVEVHNAAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN 180

Qy 181 KALPAPIEKTIASKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNG 240  
 |||||||

Db 181 KALPAPIEKTIASKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNG 240

Qy 241 QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNFSCVMHEALHNHYTQKSLSLSP 300  
 |||||||

Db 241 QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNFSCVMHEALHNHYTQKSLSLSP 300

Qy 301 GK 302

||

Db 301 GK 302

<!--EndFragment-->